CompanyGraph
Insulet Corporation
PODD · United States
Makes a tubeless, disposable patch that automatically delivers insulin to people with Type 1 diabetes every three days.
Insulet makes a tubeless insulin pump called the Omnipod 5, where a disposable pod automatically inserts a small catheter under the skin, delivers insulin for three days, and communicates wirelessly with a glucose monitor — all without any tubing connecting it to the patient's body. Every component of that pod, from the needle-retraction mechanism to the wireless chip to the plastic resin of the housing, is manufactured under a single FDA Class III clearance, so changing any one of them forces a new regulatory submission and re-validation cycle before a single pod can legally ship. That same clearance requirement applies to partnerships with glucose monitors, and because FDA requires patient safety data collected over a minimum time period, Insulet cannot simply spend its way to faster approvals — the rate at which it can add new monitor combinations is capped by clinical clock time, not capital. Patients who do switch away face losing their approved monitor pairing, disrupting the three-day ordering rhythm that endocrinology clinics have built into their workflows, and requiring their physicians to retrain on a new system, which means the regulatory structure that makes the business hard to build also makes it hard to leave.
How does this company make money?
The company sells disposable pods directly to patients and through durable medical equipment distributors. Because each pod lasts only three days, a single patient buys roughly 120 pods per year. That replacement rhythm makes revenue recurring and predictable — as long as a patient stays on the system, they are reordering continuously.
What makes this company hard to replace?
FDA interoperability clearances lock patients into specific glucose monitor combinations approved for use with Omnipod — switching to a different pump system may mean losing access to their current monitor setup. The three-day replacement cycle also becomes woven into how insurance authorization and ordering workflows are managed inside endocrinology practices, making a switch administratively disruptive for both patients and clinics. Finally, the Omnipod 5 dosing algorithms require physicians to retrain before they can manage patients on an alternative pump system, adding a meaningful professional cost to any switch.
What limits this company?
The FDA requires real patient safety data collected over a minimum period of time before it will approve a new glucose monitor pairing or a new component. No amount of money can speed up that clock, so the rate at which new versions of the closed-loop system can reach patients is capped by regulatory time, not by factory capacity.
What does this company depend on?
The company cannot operate without FDA Class III device manufacturing clearance for subcutaneous drug delivery, Bluetooth wireless certification for medical device communication, sterile injection molding facilities for disposable pod housings, Dexcom G6 continuous glucose monitor data feeds for closed-loop glucose sensing, and pharmaceutical-grade insulin formulations that are chemically compatible with the pod reservoir materials.
Who depends on this company?
Type 1 diabetic patients need a new pod every three days — if resupply stopped, their automated insulin delivery would stop with it. Endocrinologists have built their clinical workflows around the Omnipod 5 dosing algorithms, so losing the device would force them to retrain and redesign patient management from scratch. Dexcom also depends on the relationship: the Omnipod integration drives patients to buy G6 sensors, so a break in that partnership would pull down Dexcom's sensor revenue as well.
How does this company scale?
Pod manufacturing scales by adding automated injection molding and sterile packaging lines across facilities — once a line is running, it can replicate. What does not scale with capital is the clinical evidence required for each new CGM integration: FDA rules require patient safety data collected over minimum time periods, so that process stays slow no matter how much the company invests in it.
What external forces can significantly affect this company?
Medicare coverage determination policies for durable medical equipment directly control whether patients in the United States can access and afford the pods. In Europe, CE marking under the European Medical Device Regulation must be maintained for the company to sell in EU markets. Global semiconductor shortages can constrain the supply of Bluetooth chips needed for the pod's wireless communication module, which could slow manufacturing even when all other inputs are available.
Where is this company structurally vulnerable?
If the FDA issued new guidance requiring the company to resubmit approval for the existing needle-retraction design — or if a change to the pod housing material was judged to break equivalence with the original approved version — the current clearance would be invalid. The company could not legally ship pods. Every patient on a three-day replacement cycle would run out of supply, and every endocrinology practice built around the Omnipod 5 dosing schedule would lose its primary tool.